OSTX PE Ratio & Valuation,Is OSTX Overvalued — Intellectia
OSTX Relative Valuation
OSTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OSTX is overvalued; if below, it's undervalued.
Historical Valuation
OS Therapies Inc(OSTX) is now in theFairzone, suggesting that its currentforward PSratio of42.49is consideredFairlycompared with the five-year average of-5.67.The fair price ofOS Therapies Inc(OSTX)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.75
Fair
-3.43
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
OS Therapies Inc. (OSTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-3.68
EV/EBIT
OS Therapies Inc. (OSTX) has a current EV/EBIT of -3.68. The 5-year average EV/EBIT is 1.24. The thresholds are as follows: Strongly Undervalued below -5.89, Undervalued between -5.89 and -2.33, Fairly Valued between 4.81 and -2.33, Overvalued between 4.81 and 8.37, and Strongly Overvalued above 8.37. The current Forward EV/EBIT of -3.68 falls within the Undervalued range.
42.49
PS
OS Therapies Inc. (OSTX) has a current PS of 42.49. The 5-year average PS is 8.03. The thresholds are as follows: Strongly Undervalued below -21.79, Undervalued between -21.79 and -6.88, Fairly Valued between 22.94 and -6.88, Overvalued between 22.94 and 37.85, and Strongly Overvalued above 37.85. The current Forward PS of 42.49 falls within the Strongly Overvalued range.
0.00
P/OCF
OS Therapies Inc. (OSTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.55. The thresholds are as follows: Strongly Undervalued below -0.72, Undervalued between -0.72 and -0.08, Fairly Valued between 1.19 and -0.08, Overvalued between 1.19 and 1.83, and Strongly Overvalued above 1.83. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
OS Therapies Inc. (OSTX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.96. The thresholds are as follows: Strongly Undervalued below -0.80, Undervalued between -0.80 and 0.08, Fairly Valued between 1.84 and 0.08, Overvalued between 1.84 and 2.72, and Strongly Overvalued above 2.72. The current Forward P/FCF of 0.00 falls within the Undervalued range.
OS Therapies Inc (OSTX) has a current Price-to-Book (P/B) ratio of 16.65. Compared to its 3-year average P/B ratio of -18.25 , the current P/B ratio is approximately -191.22% higher. Relative to its 5-year average P/B ratio of -18.25, the current P/B ratio is about -191.22% higher. OS Therapies Inc (OSTX) has a Forward Free Cash Flow (FCF) yield of approximately -20.21%. Compared to its 3-year average FCF yield of -14.82%, the current FCF yield is approximately 36.35% lower. Relative to its 5-year average FCF yield of -14.82% , the current FCF yield is about 36.35% lower.
16.65
P/B
Median3y
-18.25
Median5y
-18.25
-20.21
FCF Yield
Median3y
-14.82
Median5y
-14.82
Competitors Valuation Multiple
The average P/S ratio for OSTX's competitors is 7.08, providing a benchmark for relative valuation. OS Therapies Inc Corp (OSTX) exhibits a P/S ratio of 42.49, which is 500% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OSTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OSTX in the past 1 year is driven by Unknown.
Is OS Therapies Inc (OSTX) currently overvalued or undervalued?
OS Therapies Inc(OSTX)is now in theFairzone, suggesting that its currentforward PSratio of 42.49is consideredFairlycompared with the five-year average of-5.67.The fair price of OS Therapies Inc(OSTX)is betweentoaccording to relative valuation methord.
What is OS Therapies Inc (OSTX) fair value?
OSTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of OS Therapies Inc (OSTX) is between to according to relative valuation methord.
How does OSTX's valuation metrics compare to the industry average?
The average P/S ratio for OSTX's competitors is 7.08, providing a benchmark for relative valuation. OS Therapies Inc Corp (OSTX) exhibits a P/S ratio of 42.49, which is 500.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for OS Therapies Inc (OSTX) as of Dec 15 2025?
As of Dec 15 2025, OS Therapies Inc (OSTX) has a P/B ratio of 16.65. This indicates that the market values OSTX at 16.65 times its book value.
What is the current FCF Yield for OS Therapies Inc (OSTX) as of Dec 15 2025?
As of Dec 15 2025, OS Therapies Inc (OSTX) has a FCF Yield of -20.21%. This means that for every dollar of OS Therapies Inc’s market capitalization, the company generates -20.21 cents in free cash flow.
What is the current Forward P/E ratio for OS Therapies Inc (OSTX) as of Dec 15 2025?
As of Dec 15 2025, OS Therapies Inc (OSTX) has a Forward P/E ratio of -3.43. This means the market is willing to pay $-3.43 for every dollar of OS Therapies Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for OS Therapies Inc (OSTX) as of Dec 15 2025?
As of Dec 15 2025, OS Therapies Inc (OSTX) has a Forward P/S ratio of 42.49. This means the market is valuing OSTX at $42.49 for every dollar of expected revenue over the next 12 months.
